"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 3 | 4 |
| 2013 | 2 | 1 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
Device-aided therapies for Parkinson's disease: "All for one, one for all, that is our device". Parkinsonism Relat Disord. 2023 Nov; 116:105862.
-
Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
-
Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
-
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 11 16; 97(20):942-957.
-
On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
-
Gut bacterial deamination of residual levodopa medication for Parkinson's disease. BMC Biol. 2020 10 20; 18(1):137.
-
Dopaminergic therapy and prefrontal activation during walking in individuals with Parkinson's disease: does the levodopa overdose hypothesis extend to gait? J Neurol. 2021 Feb; 268(2):658-668.
-
a-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease. Nat Commun. 2020 04 20; 11(1):1875.
-
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease. J Neurosci. 2020 04 29; 40(18):3675-3691.
-
Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun. 2019 01 18; 10(1):310.